Search Type: drug or dietary supplement name
Search Term: cerivastatin (BAYCOL)


Drug Profiles | Worst Pills, Best Pills Newsletter Articles | Additional Information from Public Citizen | Health Letter Articles

Drug and Dietary Supplement Profiles

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include drug profiles where your selected drug is a secondary subject of discussion

Worst Pills, Best Pills Newsletter Articles

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion

Additional Information from Public Citizen

Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion

Health Letter Articles

Search results below include Health Letter Articles where your selected drug is a secondary subject of discussion
  • Drug Safety Withdrawals: Who is Responsible for Notifying Patients? [hide all summaries]
    (December 2002)
    The following editorial, by Health Letter Editor Dr. Sidney Wolfe, appeared in the December issue of Pharmacoepidemiology and Drug Safety. Ultimately, the cost for such notification should be borne by the pharmaceutical company making the dangerous drug. Pharmacists and/or physicians, if the latter have record access, should be reimbursed for doing the company’s work. In addition, the FDA should be given new legislative authority to impose mandatory drug recalls with an enforceable withdrawal schedule governing the level and rapidity of recall and patient notification.
  • Outrage: New Study: Wait Seven Years to Use New Drugs [hide all summaries]
    (June 2002)
    A study published in the May 1, 2002 Journal of the American Medical Association (JAMA) has resulted in a major change in the Health Research Group's drug safety policy. The study, in association with physicians from the Harvard Medical School, examined the frequency and timing of the identification of new adverse drug reactions resulting in the addition of a black box warning in the drug's professional product labeling or its outright removal from the market. Three of the authors have close identification with the Health Research Group: its director, Sidney M. Wolfe, and former HRG staffers Drs. Steffi Woolhandler and David Himmelstein. The other co-authors are affiliated with the Harvard Medical School.

SHOW primary search results for cerivastatin (BAYCOL)

Copyright © 2017 Public Citizen's Health Research Group. All rights reserved. https://www.worstpills.org/